TACSTD2 and peritoneal carcinoma: In addition, sacituzumab govitecan, an approved anti-TROP2 ADC in other indications, is currently under evaluation in a phase II study (NCT06028932) in recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.